bluebird delays filing of Q1 and 2023 reports, shares fall

bluebird bio

16/04/2024 22:38

** Gene therapy developer bluebird bio's  BLUE.O  shares
fall ~3% to 96 cents in extended trading
    ** Company says its Q1 2024 report and 2023 annual report
filings will be delayed
    ** Delays due to the need to restate financial statements
for 2022 and for first three quarters of FY23, company says
    ** Work required to complete all necessary procedures is
taking longer than originally anticipated - BLUE
    ** Up to last close, stock down 70.8% in the past 12 months

    

 (Reporting by Christy Santhosh in Bengaluru)
 ((Christy.Santhosh@thomsonreuters.com))